Treatment of Lymphangioleiomyomatosis (LAM) and Patient Care

There is no FDA-approved treatment currently available to slow or stop the progression of LAM.

An experimental medicine, rapamycin (sirolimus), shows promise in shrinking tumors in the kidneys of women who have LAM. Studies are under way to find out if this medicine improves lung function in women who have LAM.

Most current treatments for LAM are aimed at easing symptoms and preventing complications. These interventions do not address the underlying disease. These treatments include inhaled bronchodilators to improve air flow in the lungs, oxygen therapy, removal of air or fluid from your chest or abdominal cavities, and lung transplantation.

Other medicines besides rapamycin are now being investigated as possible treatments for LAM.

LAM Patients Needed for Participation in Research

Learn more about Brigham and Women's Hospital

For over a century, a leader in patient care, medical education and research, with expertise in virtually every specialty of medicine and surgery.

About BWH